侨雄国际(00381.HK)附属就设合营从事电子与智能化工程等业务订谅解备忘录
侨雄国际(00381.HK)公布,於昨日(22日),公司全资附属四川侨雄置业,与四川了凡创航科技就可能於中国成立合营公司事项订立谅解备忘录。合营公司的注册资本,公司将以现金形式出资,将占合营注册资本的85%,四川了凡创航科技将以现金形式出资,将占合营注册资本的15%。
合营公司的经营范围将会包括电子与智能化工程;生物科技产品领域内的技术开发,技术转让及技术投入;医疗科技产品领域内的技术开发,技术转让及技术投入;计算机软硬件开发及推广。企业管理服务;医疗设备租赁;旅游项目开发;休闲观光活动等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.